They discover a new pulmonary syndrome related to Covid-19

In a recent study, a team of researchers from the University of San Diego (USA) and the University of Leeds (UK) has discovered a new severe pulmonary syndrome related to COVID-19. The illness, called MDA5-autoimmunity and interstitial pneumonitis contemporary with COVID-19 (MIP-C)is characterized by the presence of autoantibodies against the MDA5 enzyme and lung inflammation.

The researchers observed that Some patients with COVID-19 had a rare autoimmune disease called dermatomyositis (DM) associated with autoantibodies against MDA5.. This enzyme plays a crucial role in the detection of the SARS-CoV-2 virus, so the presence of autoantibodies against it could be preventing the proper immune response to the virus.

To better understand the relationship between COVID-19 and MDA5-associated DM, researchers used a statistical technique called “Network Odds Ratio (BoNE).” This technique allowed them to identify common patterns among patients with the disease.

The results of the study revealed that MIP-C patients had elevated levels of interleukin-15, a cytokine that can cause lung inflammation and damage. These data suggest that interleukin-15 could be a potential therapeutic target for the treatment of MIP-C.

A new name and a global call to action

Researchers have given the disease the name MIP-C, which is pronounced “mipsy.” This name was chosen to establish a connection with pediatric systemic multiinflammatory syndrome (MIS-C), another serious COVID-19-related condition affecting children.

Although the study was conducted in the United Kingdom, the researchers believe that MIP-C is not limited to that country. They have received reports of similar symptoms in patients around the world.

The research team hopes their discovery will boost research into the treatment of MIP-C and help save lives. The identification of interleukin-15 as a potential therapeutic target opens new possibilities for the development of specific drugs for this disease.

Importantly, this research is in its early stages and more studies are needed to confirm the findings and develop effective treatments for MIP-C.

Graduated from the Autonomous University of the West in 2009 and dedicated to the media since 2010 when he joined El Debate. Since then he has covered various information sources on human and health issues. He is currently the main information editor of the Health section. He has attended several national health conferences on diabetes and vaccines. He also writes various topics focused on traditional medicine, herbal remedies, prevention of chronic diseases and related news from the World Health Organization (WHO), Federal Commission for the Protection against Health Risks (Cofepris), Federal Consumer Protection Agency (Profeco). ) and Ministry of Health (SSA).

see more